Opin vísindi

Peripheral neuropathy and monoclonal gammopathy of undetermined significance : A population-based study including 15,351 cases and 58,619 matched controls

Peripheral neuropathy and monoclonal gammopathy of undetermined significance : A population-based study including 15,351 cases and 58,619 matched controls


Title: Peripheral neuropathy and monoclonal gammopathy of undetermined significance : A population-based study including 15,351 cases and 58,619 matched controls
Author: Rögnvaldsson, Sæmundur
Steingrímsson, Vilhjálmur
Turesson, Ingemar
Björkholm, Magnus
Landgren, Ola
Kristinsson, Sigurður Yngvi
Date: 2020-11
Language: English
Scope: 3
University/Institute: Landspitali - The National University Hospital of Iceland
University of Iceland
Department: Internal Medicine and Emergency Services
Faculty of Medicine
Cancer Center
Series: Haematologica; 105(11)
ISSN: 0390-6078
DOI: https://doi.org/10.3324/haematol.2019.239632
Subject: Hematology
URI: https://hdl.handle.net/20.500.11815/3346

Show full item record

Citation:

Rögnvaldsson , S , Steingrímsson , V , Turesson , I , Björkholm , M , Landgren , O & Kristinsson , S Y 2020 , ' Peripheral neuropathy and monoclonal gammopathy of undetermined significance : A population-based study including 15,351 cases and 58,619 matched controls ' , Haematologica , vol. 105 , no. 11 , pp. 2679-2681 . https://doi.org/10.3324/haematol.2019.239632

Description:

Funding Information: this research was supported by grants from the University of Iceland Research Fund, Icelandic Centre for Research (RANNIS), Landspitali University Hospital Research Fund, and Karolinska Institutet Foundations. Funding support for this publication was provided by the Memorial Sloan Kettering Core Grant (P30 CA008748) and the Perelman Family Foundation in collaboration with the Multiple Myeloma Research Foundation (MMRF) for OL. SR is a PhD candidate at the University of Iceland and this work is submitted in partial fulfilment of the requirement for a PhD. Funding Information: 1Faculty of Medicine, University of Iceland, Reykjavík, Iceland; 2Skåne University Hospital, Malmö/Lund, Sweden; 3Department of Medicine, Karolinska University Hospital Solna and Institutet, Stockholm, Sweden and 4Myeloma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA Correspondence: SAEMUNDUR ROGNVALDSSON - saer2@hi.is doi:10.3324/haematol.2019.239632 Funding: this research was supported by grants from the University of Iceland Research Fund, Icelandic Centre for Research (RANNIS), Landspitali University Hospital Research Fund, and Karolinska Institutet Foundations. Funding support for this publication was provided by the Memorial Sloan Kettering Core Grant (P30 CA008748) and the Perelman Family Foundation in collaboration with the Multiple Myeloma Research Foundation (MMRF) for OL. SR is a PhD candidate at the University of Iceland and this work is submitted in partial fulfilment of the requirement for a PhD.

Files in this item

This item appears in the following Collection(s)